Arcadia Biosciences Stock Today

RKDA Stock  USD 2.74  0.15  5.79%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 80

 
High
 
Low
High
Arcadia Biosciences is trading at 2.74 as of the 23rd of November 2024, a 5.79 percent increase since the beginning of the trading day. The stock's open price was 2.59. Arcadia Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Arcadia Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of October 2024 and ending today, the 23rd of November 2024. Click here to learn more.
Business Domain
Food, Beverage & Tobacco
IPO Date
15th of May 2015
Category
Consumer Defensive
Classification
Consumer Staples
Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. The company was incorporated in 2002 and is headquartered in Davis, California. Arcadia Bio operates under Agricultural Inputs classification in the United States and is traded on NASDAQ Exchange. The company has 1.36 M outstanding shares of which 24.86 K shares are at this time shorted by private and institutional investors with about 1.13 trading days to cover. More on Arcadia Biosciences

Moving together with Arcadia Stock

  0.71LW Lamb Weston HoldingsPairCorr

Moving against Arcadia Stock

  0.72BG Bunge LimitedPairCorr
  0.63BTI British American TobaccoPairCorr
  0.59BON Bon Natural LifePairCorr
  0.55ADM Archer Daniels Midland Sell-off TrendPairCorr
  0.54FLO Flowers FoodsPairCorr
  0.5GIS General MillsPairCorr

Arcadia Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO PresidentStanley Jacot
Thematic IdeaAgriculture (View all Themes)
Business ConcentrationAgricultural Products & Services, Food, Beverage & Tobacco, Consumer Defensive, NASDAQ Composite, Agriculture, Consumer Staples, Food Products, Agricultural Inputs, Basic Materials (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.260.2705
Sufficiently Down
Slightly volatile
Total Current Liabilities4.1 M3.6 M
Fairly Up
Pretty Stable
Non Current Liabilities Total3.2 M3.4 M
Notably Down
Slightly volatile
Total Assets35.9 M19.7 M
Way Up
Slightly volatile
Total Current Assets28.3 M15 M
Way Up
Slightly volatile
Debt Levels
Arcadia Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Arcadia Biosciences' financial leverage. It provides some insight into what part of Arcadia Biosciences' total assets is financed by creditors.
Liquidity
Arcadia Biosciences currently holds 1.01 M in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Arcadia Biosciences has a current ratio of 6.21, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Arcadia Biosciences' use of debt, we should always consider it together with its cash and equity.

Change To Inventory

466,200
Arcadia Biosciences (RKDA) is traded on NASDAQ Exchange in USA. It is located in 5950 Sherry Lane, Dallas, TX, United States, 75225 and employs 21 people. Arcadia Biosciences is listed under Agricultural Products & Services category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.74 M. Arcadia Biosciences conducts business under Food Products sector and is part of Consumer Staples industry. The entity has 1.36 M outstanding shares of which 24.86 K shares are at this time shorted by private and institutional investors with about 1.13 trading days to cover. Arcadia Biosciences currently holds about 21.23 M in cash with (15.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.96.
Check Arcadia Biosciences Probability Of Bankruptcy
Ownership Allocation
Almost 92.71 percent of Arcadia Biosciences outstanding shares are held by general public with 2.7 (percent) owned by insiders and only 4.59 % by other corporate entities.
Check Arcadia Ownership Details

Arcadia Stock Institutional Holders

InstituionRecorded OnShares
Wells Fargo & Co2024-06-30
0.0
Sabby Management Llc2024-06-30
0.0
Ubs Group Ag2024-06-30
0.0
Renaissance Technologies Corp2024-06-30
0.0
Vanguard Group Inc2024-09-30
14 K
State Street Corp2024-06-30
12.1 K
Tower Research Capital Llc2024-06-30
1.8 K
Morgan Stanley - Brokerage Accounts2024-06-30
1.2 K
Advisor Group Holdings, Inc.2024-06-30
88.0
Group One Trading, Lp2024-06-30
18.0
Bank Of America Corp2024-06-30
11.0
View Arcadia Biosciences Diagnostics

Arcadia Biosciences Historical Income Statement

At present, Arcadia Biosciences' Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 6 M, whereas Interest Expense is forecasted to decline to about 247.1 K. View More Fundamentals

Arcadia Stock Against Markets

Arcadia Biosciences Corporate Management

When determining whether Arcadia Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Arcadia Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arcadia Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arcadia Biosciences Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcadia Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Agricultural Products & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcadia Biosciences. If investors know Arcadia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcadia Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.285
Earnings Share
(6.77)
Revenue Per Share
3.802
Quarterly Revenue Growth
(0.04)
Return On Assets
(0.39)
The market value of Arcadia Biosciences is measured differently than its book value, which is the value of Arcadia that is recorded on the company's balance sheet. Investors also form their own opinion of Arcadia Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcadia Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcadia Biosciences' market value can be influenced by many factors that don't directly affect Arcadia Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcadia Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcadia Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcadia Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.